Targeting of Immune Response After Pneumococcal Vaccination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL

NCT00919321

Chronic Lymphocytic Leukemia (CLL)

COMPLETED PHASE4

Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10

NCT04912297

Pneumococcal Infections

COMPLETED

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

NCT00744263

Pneumonia, Pneumococcal Pneumococcal Infections 13-valent Pneumococcal Vaccine

COMPLETED PHASE4

Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination

NCT00143780

Bone Marrow Transplant

COMPLETED PHASE4

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

NCT00427895

Pneumococcal Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 15 volunteers receiving Pnc polysaccharide vaccine (PPV) and 12 volunteers receiving Pnc conjugate vaccine (PCV)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pneumonia group

Patients with Pnc pneumonia

Group Type NO_INTERVENTION

No interventions assigned to this group

PPV Group

Volunteers immunized with Pnc polysaccharide vaccine

Group Type ACTIVE_COMPARATOR

Pneumococcal polysaccharide vaccine

Intervention Type BIOLOGICAL

Pneumococcal polysaccharide vaccine 0.5 ml i.m.

PCV Group

Volunteers immunized with Pnc conjugate vaccine

Group Type ACTIVE_COMPARATOR

pneumococcal conjugate vaccine

Intervention Type BIOLOGICAL

pneumococcal conjugate vaccine 0.5 ml i.m.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pneumococcal polysaccharide vaccine

Pneumococcal polysaccharide vaccine 0.5 ml i.m.

Intervention Type BIOLOGICAL

pneumococcal conjugate vaccine

pneumococcal conjugate vaccine 0.5 ml i.m.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pneumovax Prevenar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females ≥ 18 and \<65 years of age.
* General good health.
* Written informed consent.
* No previous vaccination against Pnc
* No previous history of Pnc pneumonia
* In pneumonia: Diagnosis of Pnc pneumonia within a week

Exclusion Criteria

* \< 18 years, ≥65 of age.
* In vaccinees: Acute disease at the time of enrollment.
* Pregnancy or lactation.
* Known immunodeficiency or immune suppressive treatment.
* Any chronic illness that might interfere with the immune response
* Alcohol or drug abuse
* Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes